Abstract：Objective To observe the effect of Roxadustat combined with intravenous iron in the treatment of renal anemia of maintenance hemodialysis patients.Methods A total of 81 maintenance hemodialysis patients with renal anemia admitted to University Town Hospital Affiliated Chongqing Medical University Dialysis Center from January 2020 to September 2022 were selected as research objects,and they were divided into control group(41 cases)and observation group(40 cases)according to different treatment methods.The control group was treated with recombinant human erythropoietin combined with intravenous iron and the observation group was treated with Roxadustat combined with intravenous iron.The hematocrit(HCT),red blood cell count(RBC),hemoglobin(Hb),total iron binding capacity(TIBC),serum iron(SI),serum ferritin(SF)and C-reactive protein (CRP)were compared between the two groups.Results After treatment,the HCT,RBC,Hb,TIBC,SI and SF of the two groups were higher than those before treatment,the HCT,RBC,Hb,TIBC,SI and SF of the observation group were higher than those of the control group,and the CRP of the observation group was lower than that before treatment and that of the control group,with significant differences(P＜0.05).Conclusion The treatment of Roxadustat combined with intravenous iron can obviously improve the indicators of anemia in patients with uremia,significantly improve the iron metabolism index,and reduce the inflammatory factors.
何梦茜； 唐建英； 牟娇； 杨影； 陈毅； 杨璐； 宋小燕. 罗沙司他联合静脉铁剂治疗维持性血液透析患者肾性贫血的效果[J]. 中国当代医药, 2023, 30(21): 14-17.
HE Mengxi TANG Jianying MOU Jiao YANG Ying CHEN Yi YANG Lu SONG Xiaoyan. Effect of Roxadustat with intravenous iron in the treatment of renal anemia of maintenance hemodialysis patients. 中国当代医药, 2023, 30(21): 14-17.
Nakhoul G，Simon JF.Anemia of chronic kidney disease：Treat it，but not too aggressively[J].Cleve Clin J Med，2016，83（8）：613-624.
[3]
Hazin MAA.Anemia in chronic kidney disease[J].Rev Assoc Med Bras（1992），2020，66（Suppl 1）：s55-s58.
[4]
Akizawa T，Yamaguchi Y，Majikawa Y，et al.Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients[J].Ther Apher Dial，2021，25（5）：575-585.
[5]
Groenendaal-van de Meent D，Kerbusch V，Kaspera R，et al.Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat，an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor[J].Eur J Drug Metab Pharmacokinet，2021，46（1）：141-153.
Zhou QG，Jiang JP，Wu SJ，et al.Current pattern of Chinese dialysis units：a cohort study in a representative sample of units[J].Chin Med J（Engl），2012，125（19）：3434-3439.
Abboud S，Haile DJ.A novel mammalian iron-regulated protein involved in intracellular iron metabolism[J].J Biol Chem，2000，275（26）：19906-19012.
[10]
Chung J，Wessling-Resnick M.Molecular mechanisms and regulation of iron transport[J].Crit Rev Clin Lab Sci，2003，40（2）：151-182.
[11]
Conrad ME，Umbreit JN.Iron absorption and transport-an update[J].Am J Hematol，2000，64（4）：287-298.
[12]
Knutson MD，Oukka M，Koss LM，et al.Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin[J].Proc Natl Acad Sci USA，2005，102（5）：1324-1328.
Bailie GR，Larkina M，Goodkin DA，et al.Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality[J].Kidney Int，2015，87（1）：162-168.
京公网安备 11010502046607号